Table Info

Table 3.

Predictors of response to first-generation somatostatin analogues

Parameters	Higher response	Lower response	Ref.
E-cadherin	↑	↓	[31]
Ki67	↓	↑	[38–40]
Age	Older age	Younger age	[30, 41–44]
Sex	Female	Male	[45–47]
Baseline GH and IGF-1	Moderately elevated levels	High levels	[45]
T2 signal on MRI	Hypointensity	Hyperintensity	[37]
Tumor volume and invasion	↓	↑	[41]
Response to the short octreotide	Yes response (GH nadir < 3.5 ng/mL)	No response (GH nadir > 7 ng/mL)	[17]
Cytokeratin distribution pattern	Perinuclear distribution (densely granular)	Distribution in droplet; fibrous bodies > 70% (sparsely granulated)	[38]
SSTR-2 expression and SSTR-2/SSTR-5 ratio	↑	↓	[25]

STTR: somatostatin receptor; AIP: aryl hydrocarbon receptor-interacting protein

Declarations

Author contributions

IJH and LGF: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Validation.

Conflicts of interest

Both authors declare that they have no conflicts of interest.

Ethical approval

The study “Patient diagnosed with acromegaly and pituitary apoplexy after breast carcinoma treatment: challenges in diagnosis and management”, carried out by Dr. Ignacio Jiménez Hernando from the Department of Endocrinology and Nutrition Service of the Hospital General Universitario Gregorio Marañón, has been reviewed by the Ethics Committee of the Hospital General Universitario Gregorio Marañón (CEIm HGUGM), and CEIm HGUGM found no ethical impediment to the study’s publication and dissemination, as stated in Minute 19/2024 of October 21.

Consent to participate

Informed consent to participate in the study was obtained from the participant.

Consent to publication

Informed consent to publication was obtained from the relevant participant.

Availability of data and materials

The datasets that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

Not applicable.

Copyright

References

Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al.; Acromegaly Consensus Group. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27:7–22. Erratum in: Pituitary. 2024;27:88. [DOI] [PubMed] [PMC]

Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10:804–26. [DOI] [PubMed]

Danilowicz K, Sosa S. Acromegaly and Cancer: An Update. Arch Med Res. 2023;54:102914. [DOI] [PubMed]

LeRoith D, Holly JMP, Forbes BE. Insulin-like growth factors: Ligands, binding proteins, and receptors. Mol Metab. 2021;52:101245. [DOI] [PubMed] [PMC]

Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008;22:639–57. [DOI] [PubMed]

Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res. 2007;17:54–7. [DOI] [PubMed]

Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care. 2013;36:S233–9. [DOI] [PubMed] [PMC]

Boguszewski CL, Ayuk J. Management of endocrine disease: Acromegaly and cancer: an old debate revisited. Eur J Endocrinol. 2016;175:R147–56. [DOI] [PubMed]

Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151:439–46. [DOI] [PubMed]

10.

Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99:4438–46. [DOI] [PubMed]

11.

Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol. 2011;7:11–24. [DOI] [PubMed]

12.

Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord. 2008;9:41–58. [DOI] [PubMed]

13.

Corrêa LL, Lima GAB, Paiva HB, Silva CMDS, Cavallieri SA, Miranda LC, et al. Prostate cancer and acromegaly. Arq Bras Endocrinol Metabol. 2009;53:963–8. [DOI] [PubMed]

14.

Mastandrea K, Voica M, Tetlay M, Hasan F. Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer. JCEM Case Rep. 2023;1:luad069. [DOI] [PubMed] [PMC]

15.

Ershadinia N, Tritos NA. Diagnosis and Treatment of Acromegaly: An Update. Mayo Clin Proc. 2022;97:333–46. [DOI] [PubMed]

16.

Sabbah N, Wolf P, Piedvache C, Trabado S, Verdelet T, Cornu C, et al. Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays. Endocr Connect. 2021;10:1027–34. [DOI] [PubMed] [PMC]

17.

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–51. [DOI] [PubMed]

18.

Bollerslev J, Heck A, Olarescu NC. Management of endocrine disease: Individualised management of acromegaly. Eur J Endocrinol. 2019;181:R57–71. [DOI] [PubMed]

19.

Yao S, Chen W, Tavakol S, Akter F, Catalino MP, Guo X, et al. Predictors of postoperative biochemical remission in acromegaly. J Neurooncol. 2021;151:313–24. [DOI] [PubMed] [PMC]

20.

Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen O, Skeie S, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol (Oxf). 2011;74:736–43. [DOI] [PubMed]

21.

Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J. 2010;57:1035–44. [DOI] [PubMed]

22.

Paragliola RM, Corsello SM, Salvatori R. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary. 2017;20:109–15. [DOI] [PubMed]

23.

Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32:247–71. [DOI] [PubMed]

24.

Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf). 2008;68:458–65. [DOI] [PubMed]

25.

Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95:2334–42. [DOI] [PubMed]

26.

Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6:4789–96. [PubMed]

27.

Canas-Marques R, Schnitt SJ. E-cadherin immunohistochemistry in breast pathology: uses and pitfalls. Histopathology. 2016;68:57–69. [DOI] [PubMed]

28.

Elston MS, Gill AJ, Conaglen JV, Clarkson A, Cook RJ, Little NS, et al. Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin Endocrinol Metab. 2009;94:1436–42. [DOI] [PubMed]

29.

Xu B, Sano T, Yoshimoto K, Yamada S. Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr Pathol. 2002;13:341–51. [DOI] [PubMed]

30.

Venegas-Moreno E, Flores-Martinez A, Dios E, Vazquez-Borrego MC, Ibañez-Costa A, Madrazo-Atutxa A, et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med. 2019;23:3088–96. [DOI] [PubMed] [PMC]

31.

Kasuki L, Wildemberg LE, Gadelha MR. Management of endocrine disease: Personalized medicine in the treatment of acromegaly. Eur J Endocrinol. 2018;178:R89–100. [DOI] [PubMed]

32.

Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33:6–26. [DOI] [PubMed]

33.

Araujo-Castro M, Biagetti B, Torre EM, Novoa-Testa I, Cordido F, Corrales EP, et al. Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas. A series of 604 cases. J Clin Endocrinol Metab. 2024:dgae126. [DOI] [PubMed]

34.

Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf). 2012;76:96–102. [DOI] [PubMed]

35.

Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16:490–8. [DOI] [PubMed]

36.

Fernandez-Rodriguez E, Casanueva FF, Bernabeu I. Update on prognostic factors in acromegaly: Is a risk score possible? Pituitary. 2015;18:431–40. [DOI] [PubMed]

37.

Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology. 2003;228:533–8. [DOI] [PubMed]

38.

Mazal PR, Czech T, Sedivy R, Aichholzer M, Wanschitz J, Klupp N, et al. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol. 2001;20:163–71. [PubMed]

39.

Jaffrain-Rea ML, Stefano DD, Minniti G, Esposito V, Bultrini A, Ferretti E, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9:103–13. [DOI] [PubMed]

40.

DeLellis RA, Lloyd RV, Heitz PU, End C, editors. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC; 2004.

41.

Lundin P, Engström BE, Karlsson FA, Burman P. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. AJNR Am J Neuroradiol. 1997;18:765–72. [PubMed] [PMC]

42.

van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf). 1992;37:181–5. [DOI] [PubMed]

43.

Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol. 2005;152:379–87. [DOI] [PubMed]

44.

Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998;83:3411–8. [DOI] [PubMed]

45.

Dal J, Skov BG, Andersen M, Feldt-Rasmussen U, Feltoft CL, Karmisholt J, et al. Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature. Clin Endocrinol (Oxf). 2021;94:625–35. [DOI] [PubMed]

46.

Liu X, Zhu X, Zeng M, Zhuang Y, Zhou Y, Zhang Z, et al. Gender-Specific Differences in Clinical Profile and Biochemical Parameters in Patients with Cushing’s Disease: A Single Center Experience. Int J Endocrinol. 2015;2015:949620. [DOI] [PubMed] [PMC]

47.

Parkinson C, Ryder WD, Trainer PJ; Group SAS; Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab. 2001;86:5240–4. [DOI] [PubMed]